• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑膜炎流行期间的优先事项:疫苗接种还是治疗?

Priority during a meningitis epidemic: vaccination or treatment?

作者信息

Veeken H, Ritmeijer K, Hausman B

机构信息

Medical Department, Médecins sans Frontières-Holland, Amsterdam, Netherlands.

出版信息

Bull World Health Organ. 1998;76(2):135-41.

PMID:9648353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2305636/
Abstract

From November 1995 to May 1996, a meningitis epidemic occurred in northern Nigeria. More than 75,000 cases and 8440 deaths (case fatality rate (CFR), 11%) were recorded. Médecins sans Frontières, in cooperation with the Nigerian government, carried out an assistance programme (support to case management, surveillance and mass vaccination) in three states (Bauchi, Kano, Katsina) where 75% of cases occurred. Cost analysis of this assistance in Katsina State reveals that case management and mass vaccination were efficient: US$ 35 per case treated and US$ 0.64 per vaccination. There was, however, a remarkable difference in cost-effectiveness between the two strategies. The cost per death averted by improved case treatment was estimated to be US$ 396, while the cost per death averted by vaccination was estimated to be US$ 6000. In large part this difference is attributed to the late start of vaccination: more than 6 weeks after the epidemic threshold had been passed. During meningitis epidemics in countries where surveillance systems are inadequate, such as in most of sub-Saharan Africa, curative programmes should have priority.

摘要

1995年11月至1996年5月,尼日利亚北部发生了一场脑膜炎疫情。记录了超过75000例病例和8440例死亡(病死率(CFR)为11%)。无国界医生组织与尼日利亚政府合作,在病例发生率达75%的三个州(包奇、卡诺、卡齐纳)开展了一项援助计划(支持病例管理、监测和大规模疫苗接种)。对卡齐纳州这项援助的成本分析显示,病例管理和大规模疫苗接种是有效的:每治疗一例花费35美元,每接种一剂花费0.64美元。然而,这两种策略在成本效益上存在显著差异。通过改善病例治疗避免一例死亡的成本估计为396美元,而通过疫苗接种避免一例死亡的成本估计为6000美元。这种差异在很大程度上归因于疫苗接种开始得较晚:在疫情阈值过去6周多之后才开始。在撒哈拉以南非洲大部分地区等监测系统不完善的国家发生脑膜炎疫情期间,治疗方案应具有优先地位。

相似文献

1
Priority during a meningitis epidemic: vaccination or treatment?脑膜炎流行期间的优先事项:疫苗接种还是治疗?
Bull World Health Organ. 1998;76(2):135-41.
2
[An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].[1997年多哥萨瓦内地区的脑膜炎球菌性脑膜炎疫情:研究与控制策略]
Sante. 1997 Nov-Dec;7(6):384-90.
3
[Control of an epidemic of meningococcal meningitis in Central Africa].[中非地区脑膜炎球菌性脑膜炎疫情的控制]
Sante. 1996 Mar-Apr;6(2):87-95.
4
[Epidemiological and control aspects of meningococcal meningitis epidemics in Africa].[非洲脑膜炎球菌性脑膜炎疫情的流行病学及防控方面]
Sante. 1994 May-Jun;4(3):231-6.
5
[Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].[1997年塞内加尔针对脑膜炎球菌性脑膜炎和黄热病开展大规模预防性免疫接种运动的微观经济评估]
Sante. 2003 Oct-Dec;13(4):215-23.
6
[Critical review of control strategies for meningococcal meningitis epidemics in Sub-Saharan Africa].[撒哈拉以南非洲地区脑膜炎球菌性脑膜炎流行控制策略的批判性综述]
Bull Soc Pathol Exot. 2002 Mar;95(1):37-44.
7
Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria.通过大规模疫苗接种控制流行性脑膜炎球菌性脑膜炎。I. 尼日利亚北部A群和C群疫苗的进一步流行病学评估。
J Infect. 1984 Sep;9(2):190-6. doi: 10.1016/s0163-4453(84)91429-4.
8
[Neisseria meningitidis and meningitis].[脑膜炎奈瑟菌与脑膜炎]
Med Trop (Mars). 1999;59(1):68-78.
9
Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.撒哈拉以南非洲地区的脑膜炎球菌性脑膜炎:使用现有多糖疫苗进行大规模和常规疫苗接种的理由。
Bull World Health Organ. 2003;81(10):745-50; discussion 751-5. Epub 2003 Nov 25.
10
Analysis and reporting of meningococcal meningitis epidemic in north Gondar 2001-2002.2001 - 2002年北贡德尔地区脑膜炎球菌性脑膜炎疫情的分析与报告
Ethiop Med J. 2003 Oct;41(4):319-31.

引用本文的文献

1
Meningitis in HIV-positive patients in sub-Saharan Africa: a review.撒哈拉以南非洲地区HIV阳性患者的脑膜炎:综述
J Int AIDS Soc. 2014 Oct 10;17(1):19184. doi: 10.7448/IAS.17.1.19184. eCollection 2014.
2
Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts.更新当前和未来加速疾病控制、消除和根除努力的补充免疫活动运营成本的证据基础。
BMC Public Health. 2014 Jan 22;14:67. doi: 10.1186/1471-2458-14-67.
3
The state of health economic evaluation research in Nigeria: a systematic review.尼日利亚卫生经济评价研究现状:系统评价。
Pharmacoeconomics. 2010;28(7):539-53. doi: 10.2165/11536170-000000000-00000.
4
Meningococcal disease and climate.脑膜炎球菌病与气候
Glob Health Action. 2009 Nov 11;2. doi: 10.3402/gha.v2i0.2061.
5
Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.控制流行性脑膜炎球菌性脑膜炎免疫策略的成本效益综述
Pharmacoeconomics. 2005;23(4):333-43. doi: 10.2165/00019053-200523040-00004.
6
Update on meningococcal disease with emphasis on pathogenesis and clinical management.脑膜炎球菌病最新进展,重点关注发病机制与临床管理。
Clin Microbiol Rev. 2000 Jan;13(1):144-66, table of contents. doi: 10.1128/CMR.13.1.144.

本文引用的文献

1
[Physicians without borders and the meningitis epidemic in Niger in 1995: vaccinate or treat?].[无国界医生组织与1995年尼日尔的脑膜炎疫情:接种疫苗还是进行治疗?]
Ned Tijdschr Geneeskd. 1996 Aug 3;140(31):1613-6.
2
Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.接种A群脑膜炎球菌多糖疫苗后临床保护持续时间的年龄特异性差异。
Lancet. 1985 Jul 20;2(8447):114-8. doi: 10.1016/s0140-6736(85)90224-7.
3
Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group.
J Infect Dis. 1992 Aug;166(2):359-64. doi: 10.1093/infdis/166.2.359.
4
Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process.撒哈拉以南非洲地区的脑膜炎球菌性脑膜炎:流行过程的一个模型
Clin Infect Dis. 1992 Feb;14(2):515-25. doi: 10.1093/clinids/14.2.515.